7-102878422-G-T
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The ENST00000440067.4(FBXL13):c.1687C>A(p.Leu563Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000859 in 1,607,172 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L563P) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000440067.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FBXL13 | NM_001394494.2 | c.1687C>A | p.Leu563Ile | missense_variant | 16/21 | ENST00000440067.4 | NP_001381423.1 | |
FBXL13 | NR_105043.2 | n.1713C>A | non_coding_transcript_exon_variant | 16/21 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FBXL13 | ENST00000440067.4 | c.1687C>A | p.Leu563Ile | missense_variant | 16/21 | 3 | NM_001394494.2 | ENSP00000390126 | P2 |
Frequencies
GnomAD3 genomes AF: 0.0000724 AC: 11AN: 151966Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000171 AC: 42AN: 245734Hom.: 0 AF XY: 0.000166 AC XY: 22AN XY: 132830
GnomAD4 exome AF: 0.0000873 AC: 127AN: 1455088Hom.: 0 Cov.: 29 AF XY: 0.0000871 AC XY: 63AN XY: 723606
GnomAD4 genome AF: 0.0000723 AC: 11AN: 152084Hom.: 0 Cov.: 32 AF XY: 0.000135 AC XY: 10AN XY: 74320
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 26, 2021 | The c.1417C>A (p.L473I) alteration is located in exon 15 (coding exon 13) of the FBXL13 gene. This alteration results from a C to A substitution at nucleotide position 1417, causing the leucine (L) at amino acid position 473 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at